FHTX - Foghorn Therapeutics Inc Stock Price, Fair Value and News

5.95USD-0.16 (-2.62%)Market Closed

Market Summary

USD5.95-0.16

Market Closed

-2.62%

FHTX Stock Price

View Fullscreen

FHTX RSI Chart

FHTX Valuation

Market Cap

253.3M

Price/Earnings (Trailing)

-2.57

Price/Sales (Trailing)

7.42

EV/EBITDA

-1.98

Price/Free Cashflow

-2.12

FHTX Price/Sales (Trailing)

FHTX Profitability

EBT Margin

-275.80%

Return on Equity

127.51%

Return on Assets

-34.42%

Free Cashflow Yield

-47.12%

FHTX Fundamentals

FHTX Revenue

Revenue (TTM)

34.2M

Rev. Growth (Yr)

37.88%

Rev. Growth (Qtr)

-66.99%

FHTX Earnings

Earnings (TTM)

-98.4M

Earnings Growth (Yr)

16.55%

Earnings Growth (Qtr)

-68.04%

Breaking Down FHTX Revenue

Last 7 days

8.4%

Last 30 days

-17.5%

Last 90 days

101.0%

Trailing 12 Months

-0.3%

How does FHTX drawdown profile look like?

FHTX Financial Health

Current Ratio

4.11

FHTX Investor Care

Shares Dilution (1Y)

1.82%

Diluted EPS (TTM)

-2.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	20.6M	21.7M	32.6M	34.2M
2022	5.0M	9.2M	15.8M	19.2M
2021	652.3K	874.5K	1.1M	1.3M
2020	0	0	0	430.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Foghorn Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	cavalie fanny	sold	-72,133	6.5576	-11,000	chief strategy/bus ops officer
Aug 17, 2023	gottschalk adrian	gifted	-	-	-63,000	chief executive officer
Aug 17, 2023	gottschalk adrian	gifted	-	-	63,000	chief executive officer
Aug 16, 2023	agresta samuel	acquired	1,158,020	3.72	311,297	chief medical officer
Aug 16, 2023	agresta samuel	sold	-2,568,200	8.25	-311,297	chief medical officer
May 26, 2023	gottschalk adrian	gifted	-	-	-300,000	chief executive officer
Feb 17, 2023	gottschalk adrian	gifted	-	-	-4,371	chief executive officer
Feb 17, 2023	gottschalk adrian	gifted	-	-	4,371	chief executive officer
Feb 17, 2023	gottschalk adrian	sold	-	-	-184,939	chief executive officer
Oct 25, 2022	gottschalk adrian	acquired	-	-	4,371	chief executive officer

Which funds bought or sold FHTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	added	0.08	1,327	33,577	-%
May 01, 2024	Alta Wealth Advisors LLC	unchanged	-	7,809	201,515	0.10%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	TFC Financial Management, Inc.	unchanged	-	32.00	826	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	20.00	20.00	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	-	13.00	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	6.24	38,834	407,761	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	14,000	14,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.3	-14,000	5,000	-%
Apr 23, 2024	WASHINGTON TRUST Co	unchanged	-	390	10,065	-%

Are Funds Buying or Selling FHTX?

Are funds buying FHTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FHTX

No. of Funds

Unveiling Foghorn Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Dec 13, 2021	eli lilly & co	9.7%	4e+06	SC 13G
Apr 19, 2021	kadoch cigall	11.05%	3,957,712	SC 13G
Feb 08, 2021	fmr llc	-	0	SC 13G
Feb 04, 2021	klarman family foundation	5.97%	2,139,639	SC 13G

Recent SEC filings of Foghorn Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	ARS	ARS
May 03, 2024	DEF 14A	DEF 14A
May 03, 2024	DEFA14A	DEFA14A
Apr 17, 2024	3	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 07, 2024	10-K	Annual Report
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Foghorn Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Foghorn Therapeutics Inc News

Latest updates

Foghorn Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-67.0%	5,769,000	17,478,000	5,599,000	5,309,000	4,184,000	6,634,000	4,490,000	3,920,000	713,000	41,000	279,000	286,000	232,500	179,000
Operating Expenses	-9.6%	31,227,000	34,559,000	37,649,000	38,626,000	36,070,000	34,893,000	33,678,000	31,724,000	28,795,000	26,302,000	23,540,000	23,416,000	21,030,000	18,668,000
S&GA Expenses	-15.5%	7,022,000	8,308,000	8,401,000	8,641,000	7,862,000	7,965,000	7,704,000	7,216,000	6,332,000	5,808,000	4,898,000	4,690,000	4,559,000	2,555,000
R&D Expenses	-7.8%	24,205,000	26,251,000	29,248,000	29,985,000	28,208,000	26,928,000	25,974,000	24,508,000	22,463,000	20,494,000	18,642,000	18,726,000	16,471,000	16,113,000
EBITDA Margin	14.8%	-2.55	-3.00	-5.05	-5.26	-5.49	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	236,000	499,000	495,000	486,000	321,000	202,000
Income Taxes	168.4%	1,981,000	738,000	900,000	600,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-62.6%	-22,120,000	-13,607,000	-28,545,000	-29,928,000	-28,886,000	-25,769,000	-27,313,000	-26,914,000	-	-	-	-	-	-
EBT Margin	11.0%	-2.76	-3.10	-5.21	-5.43	-5.66	-	-	-	-	-	-	-	-	-
Net Income	-68.0%	-24,106,000	-14,345,000	-29,487,000	-30,488,000	-28,886,000	-25,769,000	-27,313,000	-26,914,000	-29,143,000	-26,080,000	-23,111,000	-22,986,000	-20,758,000	-18,367,000
Net Income Margin	9.1%	-2.88	-3.17	-5.28	-5.45	-5.66	-6.93	-11.94	-21.25	-76.82	-84.74	-97.45	-119	-	-
Free Cashflow	-1.0%	-27,578,000	-27,292,000	-32,644,000	-31,816,000	-29,193,000	-20,316,000	-29,376,000	271,287,000	11,802,000	-20,732,000	-19,692,000	-24,941,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-8.8%	286	313	340	373	405	434	457	488	520	186	209	230	256	142	22.00
Current Assets	-9.5%	240	265	290	321	351	378	400	430	460	124	145	165	191	78.00	17.00
Cash Equivalents	14.3%	80.00	70.00	58.00	51.00	52.00	88.00	61.00	214	103	58.00	125	66.00	95.00	75.00	17.00
Liabilities	-2.1%	363	371	389	397	405	410	409	416	423	105	104	105	109	99.00	24.00
Current Liabilities	12.4%	58.00	52.00	57.00	56.00	55.00	55.00	48.00	48.00	49.00	19.00	16.00	16.00	19.00	21.00	13.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	20.00	20.00	20.00	20.00	9.00	11.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	9.00	11.00
Shareholder's Equity	-Infinity%	-77.19	-	-	-	0.00	24.00	48.00	72.00	97.00	81.00	104	125	146	-	-
Retained Earnings	-5.4%	-471	-447	-433	-403	-373	-344	-318	-291	-264	-235	-209	-185	-162	-142	-94.14
Additional Paid-In Capital	0.8%	395	392	386	382	377	373	369	365	361	316	313	311	309	9.00	6.00
Shares Outstanding	0.2%	42.00	42.00	42.00	42.00	42.00	42.00	42.00	41.00	41.00	37.00	37.00	37.00	-	-	-
Float	-	-	-	200	-	-	-	335	-	-	-	209	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-1.2%	-27,541	-27,210	-32,175	-31,180	-28,924	-19,986	-29,012	271,534	11,882	-20,502	-18,483	-23,147	-10,655	2,726	-12,595	-10,762	-	-
Share Based Compensation	-25.5%	3,051	4,094	4,470	4,572	3,781	3,802	3,509	3,244	-	2,370	2,042	1,888	1,078	877	489	517	-	443
Cashflow From Investing	-2.7%	37,385	38,426	39,134	29,505	-6,507	46,051	-124,457	-159,409	9,673	-47,328	77,089	-3,261	-100,220	-5,425	-2,248	-1,021	-	-
Cashflow From Financing	-86.6%	186	1,387	103	102	16.00	333	1,030	384	21,740	505	111	62.00	128,509	40,754	47,963	247	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FHTX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 34,155	$ 19,228
Operating expenses:
Research and development	109,689	105,618
General and administrative	32,372	30,747
Total operating expenses	142,061	136,365
Loss from operations	(107,906)	(117,137)
Other income (expense):
Interest income	10,875	5,675
Other income, net	2,831	2,580
Total other income, net	13,706	8,255
Loss before income taxes	(94,200)	(108,882)
Provision for income taxes	(4,226)	0
Net loss	$ (98,426)	$ (108,882)
Net loss per share attributable to common stockholders—basic (in dollars per share)	$ (2.34)	$ (2.62)
Net loss per share attributable to common stockholders—diluted (in dollars per share)	$ (2.34)	$ (2.62)
Weighted average common shares outstanding—basic (in shares)	41,974,484	41,591,433
Weighted average common shares outstanding—diluted (in shares)	41,974,484	41,591,433
Comprehensive loss:
Net loss	$ (98,426)	$ (108,882)
Other comprehensive loss:
Unrealized gains (losses) on marketable securities	3,160	(3,976)
Total other comprehensive gain (loss)	3,160	(3,976)
Total comprehensive loss	$ (95,266)	$ (112,858)
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaboration Revenue [Member]	Collaboration Revenue [Member]

FHTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 80,336	$ 52,214
Marketable securities	153,721	293,584
Prepaid expenses and other current assets	6,124	5,601
Total current assets	240,181	351,399
Property and equipment, net	12,956	15,311
Restricted cash	1,708	1,708
Other assets	1,115	2,379
Operating lease right-of-use assets	29,956	34,086
Total assets	285,916	404,883
Current liabilities:
Accounts payable	6,260	5,414
Accrued expenses and other current liabilities	9,108	11,001
Operating lease liabilities	8,518	5,970
Deferred revenue	34,550	32,820
Total current liabilities	58,436	55,205
Operating lease liabilities, net of current portion	36,555	45,537
Deferred revenue, net of current portion	268,115	304,000
Other liabilities	0	29
Total liabilities	363,106	404,771
Commitments and contingencies (Note 11)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 175,000,000 shares authorized at December 31, 2023 and 2022; 42,282,040 shares issued and outstanding at December 31, 2023 and 41,803,436 shares issued and outstanding at December 31, 2022	4	4
Additional paid-in capital	395,196	377,232
Accumulated other comprehensive loss	(826)	(3,986)
Accumulated deficit	(471,564)	(373,138)
Total stockholders’ equity (deficit)	(77,190)	112
Total liabilities and stockholders’ equity (deficit)	$ 285,916	$ 404,883

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Adrian H. B. Gottschalk
WEBSITE	https://foghorntx.com
INDUSTRY	Biotechnology
EMPLOYEES	161

Foghorn Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Foghorn Therapeutics Inc? What does FHTX stand for in stocks?

FHTX is the stock ticker symbol of Foghorn Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Foghorn Therapeutics Inc (FHTX)?

As of Fri May 03 2024, market cap of Foghorn Therapeutics Inc is 253.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FHTX stock?

You can check FHTX's fair value in chart for subscribers.

What is the fair value of FHTX stock?

You can check FHTX's fair value in chart for subscribers. The fair value of Foghorn Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Foghorn Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FHTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Foghorn Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FHTX is over valued or under valued. Whether Foghorn Therapeutics Inc is cheap or expensive depends on the assumptions which impact Foghorn Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FHTX.

What is Foghorn Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, FHTX's PE ratio (Price to Earnings) is -2.57 and Price to Sales (PS) ratio is 7.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FHTX PE ratio will change depending on the future growth rate expectations of investors.